Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy as neoadjuvant treatment for advanced ovarian cancer
ChiCTR2500101645Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Peking University Third Hospital. Primary endpoint: R0 resection rate. Started Apr 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR2500101645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101645.